nodes	percent_of_prediction	percent_of_DWPC	metapath
Eprosartan—AGTR1—breast cancer	0.419	1	CbGaD
Eprosartan—CYP2C9—Anastrozole—breast cancer	0.0423	0.12	CbGbCtD
Eprosartan—ABCC2—Tamoxifen—breast cancer	0.042	0.119	CbGbCtD
Eprosartan—ABCC2—Paclitaxel—breast cancer	0.0327	0.0929	CbGbCtD
Eprosartan—ABCC2—Irinotecan—breast cancer	0.0323	0.0916	CbGbCtD
Eprosartan—CYP2C9—Idarubicin—breast cancer	0.032	0.0909	CbGbCtD
Eprosartan—ABCC2—Carboplatin—breast cancer	0.0308	0.0874	CbGbCtD
Eprosartan—ABCC2—Vinblastine—breast cancer	0.0287	0.0815	CbGbCtD
Eprosartan—ABCC2—Docetaxel—breast cancer	0.0237	0.0672	CbGbCtD
Eprosartan—ABCC2—Doxorubicin—breast cancer	0.0176	0.0501	CbGbCtD
Eprosartan—CYP2C9—Capecitabine—breast cancer	0.0175	0.0498	CbGbCtD
Eprosartan—ABCC2—Methotrexate—breast cancer	0.0171	0.0485	CbGbCtD
Eprosartan—CYP2C9—Tamoxifen—breast cancer	0.0141	0.0401	CbGbCtD
Eprosartan—CYP2C9—Paclitaxel—breast cancer	0.011	0.0312	CbGbCtD
Eprosartan—CYP2C9—Fluorouracil—breast cancer	0.0104	0.0295	CbGbCtD
Eprosartan—Losartan—SLCO1B1—breast cancer	0.0011	0.418	CrCbGaD
Eprosartan—Losartan—AGTR1—breast cancer	0.000882	0.335	CrCbGaD
Eprosartan—Losartan—CYP3A4—breast cancer	0.000239	0.091	CrCbGaD
Eprosartan—Losartan—ALB—breast cancer	0.000209	0.0794	CrCbGaD
Eprosartan—Losartan—ABCB1—breast cancer	0.000199	0.0758	CrCbGaD
Eprosartan—AGTR1—nipple—breast cancer	0.000131	0.149	CbGeAlD
Eprosartan—AGTR1—epithelium—breast cancer	8.81e-05	0.1	CbGeAlD
Eprosartan—CYP2C9—mammary gland—breast cancer	7.62e-05	0.0865	CbGeAlD
Eprosartan—AGTR1—pituitary gland—breast cancer	7.15e-05	0.0812	CbGeAlD
Eprosartan—AGTR1—adipose tissue—breast cancer	7.12e-05	0.0809	CbGeAlD
Eprosartan—AGTR1—female reproductive system—breast cancer	6.54e-05	0.0744	CbGeAlD
Eprosartan—AGTR1—adrenal gland—breast cancer	6.38e-05	0.0726	CbGeAlD
Eprosartan—AGTR1—endocrine gland—breast cancer	5.54e-05	0.0629	CbGeAlD
Eprosartan—ABCC2—female reproductive system—breast cancer	4.73e-05	0.0537	CbGeAlD
Eprosartan—ABCC2—adrenal gland—breast cancer	4.61e-05	0.0524	CbGeAlD
Eprosartan—Diarrhoea—Gemcitabine—breast cancer	4.41e-05	0.000265	CcSEcCtD
Eprosartan—Renal failure—Doxorubicin—breast cancer	4.4e-05	0.000264	CcSEcCtD
Eprosartan—Neuropathy peripheral—Doxorubicin—breast cancer	4.39e-05	0.000263	CcSEcCtD
Eprosartan—Dizziness—Irinotecan—breast cancer	4.38e-05	0.000262	CcSEcCtD
Eprosartan—Anorexia—Docetaxel—breast cancer	4.36e-05	0.000262	CcSEcCtD
Eprosartan—Shock—Capecitabine—breast cancer	4.36e-05	0.000261	CcSEcCtD
Eprosartan—Rhinitis—Epirubicin—breast cancer	4.35e-05	0.000261	CcSEcCtD
Eprosartan—Conjunctivitis—Doxorubicin—breast cancer	4.35e-05	0.000261	CcSEcCtD
Eprosartan—Urinary tract infection—Doxorubicin—breast cancer	4.35e-05	0.000261	CcSEcCtD
Eprosartan—Diarrhoea—Fluorouracil—breast cancer	4.34e-05	0.00026	CcSEcCtD
Eprosartan—Thrombocytopenia—Capecitabine—breast cancer	4.34e-05	0.00026	CcSEcCtD
Eprosartan—Tinnitus—Methotrexate—breast cancer	4.33e-05	0.000259	CcSEcCtD
Eprosartan—Tachycardia—Capecitabine—breast cancer	4.32e-05	0.000259	CcSEcCtD
Eprosartan—Pharyngitis—Epirubicin—breast cancer	4.31e-05	0.000259	CcSEcCtD
Eprosartan—Urticaria—Paclitaxel—breast cancer	4.29e-05	0.000257	CcSEcCtD
Eprosartan—Hyperhidrosis—Capecitabine—breast cancer	4.28e-05	0.000257	CcSEcCtD
Eprosartan—Oedema peripheral—Epirubicin—breast cancer	4.28e-05	0.000257	CcSEcCtD
Eprosartan—Hypotension—Docetaxel—breast cancer	4.28e-05	0.000256	CcSEcCtD
Eprosartan—Haematuria—Doxorubicin—breast cancer	4.27e-05	0.000256	CcSEcCtD
Eprosartan—Abdominal pain—Paclitaxel—breast cancer	4.27e-05	0.000256	CcSEcCtD
Eprosartan—Body temperature increased—Paclitaxel—breast cancer	4.27e-05	0.000256	CcSEcCtD
Eprosartan—Epistaxis—Doxorubicin—breast cancer	4.22e-05	0.000253	CcSEcCtD
Eprosartan—Anorexia—Capecitabine—breast cancer	4.22e-05	0.000253	CcSEcCtD
Eprosartan—Vomiting—Irinotecan—breast cancer	4.21e-05	0.000252	CcSEcCtD
Eprosartan—Vomiting—Mitoxantrone—breast cancer	4.21e-05	0.000252	CcSEcCtD
Eprosartan—Sinusitis—Doxorubicin—breast cancer	4.2e-05	0.000252	CcSEcCtD
Eprosartan—Dizziness—Fluorouracil—breast cancer	4.19e-05	0.000251	CcSEcCtD
Eprosartan—Visual impairment—Epirubicin—breast cancer	4.19e-05	0.000251	CcSEcCtD
Eprosartan—Rash—Irinotecan—breast cancer	4.17e-05	0.00025	CcSEcCtD
Eprosartan—Rash—Mitoxantrone—breast cancer	4.17e-05	0.00025	CcSEcCtD
Eprosartan—Dermatitis—Irinotecan—breast cancer	4.17e-05	0.00025	CcSEcCtD
Eprosartan—Dermatitis—Mitoxantrone—breast cancer	4.17e-05	0.00025	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Docetaxel—breast cancer	4.17e-05	0.00025	CcSEcCtD
Eprosartan—Chills—Methotrexate—breast cancer	4.16e-05	0.00025	CcSEcCtD
Eprosartan—Headache—Mitoxantrone—breast cancer	4.15e-05	0.000249	CcSEcCtD
Eprosartan—Headache—Irinotecan—breast cancer	4.15e-05	0.000249	CcSEcCtD
Eprosartan—Hypotension—Capecitabine—breast cancer	4.14e-05	0.000248	CcSEcCtD
Eprosartan—Insomnia—Docetaxel—breast cancer	4.14e-05	0.000248	CcSEcCtD
Eprosartan—Paraesthesia—Docetaxel—breast cancer	4.11e-05	0.000246	CcSEcCtD
Eprosartan—Vomiting—Gemcitabine—breast cancer	4.1e-05	0.000246	CcSEcCtD
Eprosartan—Bradycardia—Doxorubicin—breast cancer	4.09e-05	0.000245	CcSEcCtD
Eprosartan—Dyspnoea—Docetaxel—breast cancer	4.08e-05	0.000245	CcSEcCtD
Eprosartan—Somnolence—Docetaxel—breast cancer	4.07e-05	0.000244	CcSEcCtD
Eprosartan—Rash—Gemcitabine—breast cancer	4.07e-05	0.000244	CcSEcCtD
Eprosartan—Dermatitis—Gemcitabine—breast cancer	4.06e-05	0.000244	CcSEcCtD
Eprosartan—Tinnitus—Epirubicin—breast cancer	4.05e-05	0.000243	CcSEcCtD
Eprosartan—Headache—Gemcitabine—breast cancer	4.04e-05	0.000242	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Capecitabine—breast cancer	4.04e-05	0.000242	CcSEcCtD
Eprosartan—Vomiting—Fluorouracil—breast cancer	4.03e-05	0.000242	CcSEcCtD
Eprosartan—Rhinitis—Doxorubicin—breast cancer	4.03e-05	0.000242	CcSEcCtD
Eprosartan—Dyspepsia—Docetaxel—breast cancer	4.03e-05	0.000241	CcSEcCtD
Eprosartan—Insomnia—Capecitabine—breast cancer	4.01e-05	0.00024	CcSEcCtD
Eprosartan—ABCC2—endocrine gland—breast cancer	4e-05	0.0455	CbGeAlD
Eprosartan—Rash—Fluorouracil—breast cancer	4e-05	0.00024	CcSEcCtD
Eprosartan—Dermatitis—Fluorouracil—breast cancer	3.99e-05	0.000239	CcSEcCtD
Eprosartan—Pharyngitis—Doxorubicin—breast cancer	3.99e-05	0.000239	CcSEcCtD
Eprosartan—Paraesthesia—Capecitabine—breast cancer	3.98e-05	0.000239	CcSEcCtD
Eprosartan—Decreased appetite—Docetaxel—breast cancer	3.98e-05	0.000238	CcSEcCtD
Eprosartan—Hypersensitivity—Paclitaxel—breast cancer	3.98e-05	0.000238	CcSEcCtD
Eprosartan—Headache—Fluorouracil—breast cancer	3.97e-05	0.000238	CcSEcCtD
Eprosartan—Oedema peripheral—Doxorubicin—breast cancer	3.96e-05	0.000237	CcSEcCtD
Eprosartan—Dyspnoea—Capecitabine—breast cancer	3.95e-05	0.000237	CcSEcCtD
Eprosartan—Fatigue—Docetaxel—breast cancer	3.94e-05	0.000237	CcSEcCtD
Eprosartan—Nausea—Irinotecan—breast cancer	3.93e-05	0.000236	CcSEcCtD
Eprosartan—Nausea—Mitoxantrone—breast cancer	3.93e-05	0.000236	CcSEcCtD
Eprosartan—Pain—Docetaxel—breast cancer	3.91e-05	0.000235	CcSEcCtD
Eprosartan—Constipation—Docetaxel—breast cancer	3.91e-05	0.000235	CcSEcCtD
Eprosartan—Back pain—Methotrexate—breast cancer	3.91e-05	0.000234	CcSEcCtD
Eprosartan—Dyspepsia—Capecitabine—breast cancer	3.9e-05	0.000234	CcSEcCtD
Eprosartan—Chills—Epirubicin—breast cancer	3.9e-05	0.000234	CcSEcCtD
Eprosartan—Visual impairment—Doxorubicin—breast cancer	3.87e-05	0.000232	CcSEcCtD
Eprosartan—Asthenia—Paclitaxel—breast cancer	3.87e-05	0.000232	CcSEcCtD
Eprosartan—Decreased appetite—Capecitabine—breast cancer	3.85e-05	0.000231	CcSEcCtD
Eprosartan—Nausea—Gemcitabine—breast cancer	3.83e-05	0.00023	CcSEcCtD
Eprosartan—AGTR1—lymph node—breast cancer	3.83e-05	0.0435	CbGeAlD
Eprosartan—Fatigue—Capecitabine—breast cancer	3.82e-05	0.000229	CcSEcCtD
Eprosartan—Pruritus—Paclitaxel—breast cancer	3.82e-05	0.000229	CcSEcCtD
Eprosartan—Constipation—Capecitabine—breast cancer	3.79e-05	0.000227	CcSEcCtD
Eprosartan—Pain—Capecitabine—breast cancer	3.79e-05	0.000227	CcSEcCtD
Eprosartan—Feeling abnormal—Docetaxel—breast cancer	3.77e-05	0.000226	CcSEcCtD
Eprosartan—Nausea—Fluorouracil—breast cancer	3.77e-05	0.000226	CcSEcCtD
Eprosartan—Ill-defined disorder—Methotrexate—breast cancer	3.75e-05	0.000225	CcSEcCtD
Eprosartan—Tinnitus—Doxorubicin—breast cancer	3.75e-05	0.000225	CcSEcCtD
Eprosartan—Gastrointestinal pain—Docetaxel—breast cancer	3.74e-05	0.000224	CcSEcCtD
Eprosartan—Flatulence—Epirubicin—breast cancer	3.73e-05	0.000223	CcSEcCtD
Eprosartan—Tension—Epirubicin—breast cancer	3.71e-05	0.000222	CcSEcCtD
Eprosartan—Diarrhoea—Paclitaxel—breast cancer	3.69e-05	0.000221	CcSEcCtD
Eprosartan—Nervousness—Epirubicin—breast cancer	3.67e-05	0.00022	CcSEcCtD
Eprosartan—Back pain—Epirubicin—breast cancer	3.66e-05	0.000219	CcSEcCtD
Eprosartan—Feeling abnormal—Capecitabine—breast cancer	3.65e-05	0.000219	CcSEcCtD
Eprosartan—Malaise—Methotrexate—breast cancer	3.64e-05	0.000218	CcSEcCtD
Eprosartan—Muscle spasms—Epirubicin—breast cancer	3.64e-05	0.000218	CcSEcCtD
Eprosartan—Vertigo—Methotrexate—breast cancer	3.63e-05	0.000218	CcSEcCtD
Eprosartan—Gastrointestinal pain—Capecitabine—breast cancer	3.62e-05	0.000217	CcSEcCtD
Eprosartan—Body temperature increased—Docetaxel—breast cancer	3.62e-05	0.000217	CcSEcCtD
Eprosartan—Abdominal pain—Docetaxel—breast cancer	3.62e-05	0.000217	CcSEcCtD
Eprosartan—Chills—Doxorubicin—breast cancer	3.61e-05	0.000216	CcSEcCtD
Eprosartan—Dizziness—Paclitaxel—breast cancer	3.57e-05	0.000214	CcSEcCtD
Eprosartan—Cough—Methotrexate—breast cancer	3.53e-05	0.000211	CcSEcCtD
Eprosartan—Urticaria—Capecitabine—breast cancer	3.52e-05	0.000211	CcSEcCtD
Eprosartan—Ill-defined disorder—Epirubicin—breast cancer	3.51e-05	0.00021	CcSEcCtD
Eprosartan—Abdominal pain—Capecitabine—breast cancer	3.5e-05	0.00021	CcSEcCtD
Eprosartan—Body temperature increased—Capecitabine—breast cancer	3.5e-05	0.00021	CcSEcCtD
Eprosartan—Flatulence—Doxorubicin—breast cancer	3.45e-05	0.000207	CcSEcCtD
Eprosartan—Myalgia—Methotrexate—breast cancer	3.44e-05	0.000206	CcSEcCtD
Eprosartan—Chest pain—Methotrexate—breast cancer	3.44e-05	0.000206	CcSEcCtD
Eprosartan—Arthralgia—Methotrexate—breast cancer	3.44e-05	0.000206	CcSEcCtD
Eprosartan—Tension—Doxorubicin—breast cancer	3.43e-05	0.000206	CcSEcCtD
Eprosartan—Vomiting—Paclitaxel—breast cancer	3.43e-05	0.000206	CcSEcCtD
Eprosartan—Malaise—Epirubicin—breast cancer	3.41e-05	0.000204	CcSEcCtD
Eprosartan—Rash—Paclitaxel—breast cancer	3.4e-05	0.000204	CcSEcCtD
Eprosartan—Dermatitis—Paclitaxel—breast cancer	3.4e-05	0.000204	CcSEcCtD
Eprosartan—Discomfort—Methotrexate—breast cancer	3.4e-05	0.000204	CcSEcCtD
Eprosartan—Nervousness—Doxorubicin—breast cancer	3.4e-05	0.000204	CcSEcCtD
Eprosartan—Vertigo—Epirubicin—breast cancer	3.4e-05	0.000204	CcSEcCtD
Eprosartan—Syncope—Epirubicin—breast cancer	3.39e-05	0.000203	CcSEcCtD
Eprosartan—Back pain—Doxorubicin—breast cancer	3.38e-05	0.000203	CcSEcCtD
Eprosartan—Headache—Paclitaxel—breast cancer	3.38e-05	0.000203	CcSEcCtD
Eprosartan—Hypersensitivity—Docetaxel—breast cancer	3.37e-05	0.000202	CcSEcCtD
Eprosartan—Muscle spasms—Doxorubicin—breast cancer	3.36e-05	0.000202	CcSEcCtD
Eprosartan—Palpitations—Epirubicin—breast cancer	3.34e-05	0.0002	CcSEcCtD
Eprosartan—Loss of consciousness—Epirubicin—breast cancer	3.32e-05	0.000199	CcSEcCtD
Eprosartan—Cough—Epirubicin—breast cancer	3.3e-05	0.000198	CcSEcCtD
Eprosartan—Asthenia—Docetaxel—breast cancer	3.28e-05	0.000197	CcSEcCtD
Eprosartan—Hypersensitivity—Capecitabine—breast cancer	3.26e-05	0.000196	CcSEcCtD
Eprosartan—Ill-defined disorder—Doxorubicin—breast cancer	3.25e-05	0.000195	CcSEcCtD
Eprosartan—Pruritus—Docetaxel—breast cancer	3.24e-05	0.000194	CcSEcCtD
Eprosartan—Thrombocytopenia—Methotrexate—breast cancer	3.23e-05	0.000194	CcSEcCtD
Eprosartan—Myalgia—Epirubicin—breast cancer	3.22e-05	0.000193	CcSEcCtD
Eprosartan—Chest pain—Epirubicin—breast cancer	3.22e-05	0.000193	CcSEcCtD
Eprosartan—Arthralgia—Epirubicin—breast cancer	3.22e-05	0.000193	CcSEcCtD
Eprosartan—Anxiety—Epirubicin—breast cancer	3.21e-05	0.000192	CcSEcCtD
Eprosartan—Nausea—Paclitaxel—breast cancer	3.21e-05	0.000192	CcSEcCtD
Eprosartan—Hyperhidrosis—Methotrexate—breast cancer	3.19e-05	0.000191	CcSEcCtD
Eprosartan—Discomfort—Epirubicin—breast cancer	3.18e-05	0.000191	CcSEcCtD
Eprosartan—Asthenia—Capecitabine—breast cancer	3.18e-05	0.000191	CcSEcCtD
Eprosartan—Malaise—Doxorubicin—breast cancer	3.16e-05	0.000189	CcSEcCtD
Eprosartan—CYP2C9—female reproductive system—breast cancer	3.15e-05	0.0358	CbGeAlD
Eprosartan—Dry mouth—Epirubicin—breast cancer	3.15e-05	0.000189	CcSEcCtD
Eprosartan—Vertigo—Doxorubicin—breast cancer	3.14e-05	0.000188	CcSEcCtD
Eprosartan—Anorexia—Methotrexate—breast cancer	3.14e-05	0.000188	CcSEcCtD
Eprosartan—Syncope—Doxorubicin—breast cancer	3.14e-05	0.000188	CcSEcCtD
Eprosartan—Pruritus—Capecitabine—breast cancer	3.13e-05	0.000188	CcSEcCtD
Eprosartan—Diarrhoea—Docetaxel—breast cancer	3.13e-05	0.000188	CcSEcCtD
Eprosartan—Palpitations—Doxorubicin—breast cancer	3.09e-05	0.000185	CcSEcCtD
Eprosartan—Hypotension—Methotrexate—breast cancer	3.08e-05	0.000185	CcSEcCtD
Eprosartan—Loss of consciousness—Doxorubicin—breast cancer	3.08e-05	0.000184	CcSEcCtD
Eprosartan—Cough—Doxorubicin—breast cancer	3.05e-05	0.000183	CcSEcCtD
Eprosartan—Shock—Epirubicin—breast cancer	3.04e-05	0.000182	CcSEcCtD
Eprosartan—Diarrhoea—Capecitabine—breast cancer	3.03e-05	0.000182	CcSEcCtD
Eprosartan—Dizziness—Docetaxel—breast cancer	3.03e-05	0.000181	CcSEcCtD
Eprosartan—Thrombocytopenia—Epirubicin—breast cancer	3.02e-05	0.000181	CcSEcCtD
Eprosartan—Tachycardia—Epirubicin—breast cancer	3.01e-05	0.000181	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Methotrexate—breast cancer	3e-05	0.00018	CcSEcCtD
Eprosartan—Hyperhidrosis—Epirubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Eprosartan—Insomnia—Methotrexate—breast cancer	2.98e-05	0.000179	CcSEcCtD
Eprosartan—Myalgia—Doxorubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Eprosartan—Chest pain—Doxorubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Eprosartan—Arthralgia—Doxorubicin—breast cancer	2.98e-05	0.000179	CcSEcCtD
Eprosartan—Anxiety—Doxorubicin—breast cancer	2.97e-05	0.000178	CcSEcCtD
Eprosartan—Paraesthesia—Methotrexate—breast cancer	2.96e-05	0.000178	CcSEcCtD
Eprosartan—Discomfort—Doxorubicin—breast cancer	2.94e-05	0.000176	CcSEcCtD
Eprosartan—Anorexia—Epirubicin—breast cancer	2.94e-05	0.000176	CcSEcCtD
Eprosartan—Dyspnoea—Methotrexate—breast cancer	2.94e-05	0.000176	CcSEcCtD
Eprosartan—Somnolence—Methotrexate—breast cancer	2.93e-05	0.000176	CcSEcCtD
Eprosartan—Dizziness—Capecitabine—breast cancer	2.93e-05	0.000176	CcSEcCtD
Eprosartan—Dry mouth—Doxorubicin—breast cancer	2.91e-05	0.000175	CcSEcCtD
Eprosartan—Vomiting—Docetaxel—breast cancer	2.91e-05	0.000174	CcSEcCtD
Eprosartan—Dyspepsia—Methotrexate—breast cancer	2.9e-05	0.000174	CcSEcCtD
Eprosartan—Rash—Docetaxel—breast cancer	2.88e-05	0.000173	CcSEcCtD
Eprosartan—Hypotension—Epirubicin—breast cancer	2.88e-05	0.000173	CcSEcCtD
Eprosartan—Dermatitis—Docetaxel—breast cancer	2.88e-05	0.000173	CcSEcCtD
Eprosartan—Decreased appetite—Methotrexate—breast cancer	2.87e-05	0.000172	CcSEcCtD
Eprosartan—Headache—Docetaxel—breast cancer	2.87e-05	0.000172	CcSEcCtD
Eprosartan—Fatigue—Methotrexate—breast cancer	2.84e-05	0.00017	CcSEcCtD
Eprosartan—Pain—Methotrexate—breast cancer	2.82e-05	0.000169	CcSEcCtD
Eprosartan—Vomiting—Capecitabine—breast cancer	2.82e-05	0.000169	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Epirubicin—breast cancer	2.81e-05	0.000169	CcSEcCtD
Eprosartan—Shock—Doxorubicin—breast cancer	2.81e-05	0.000168	CcSEcCtD
Eprosartan—Thrombocytopenia—Doxorubicin—breast cancer	2.8e-05	0.000168	CcSEcCtD
Eprosartan—Rash—Capecitabine—breast cancer	2.79e-05	0.000167	CcSEcCtD
Eprosartan—Insomnia—Epirubicin—breast cancer	2.79e-05	0.000167	CcSEcCtD
Eprosartan—Dermatitis—Capecitabine—breast cancer	2.79e-05	0.000167	CcSEcCtD
Eprosartan—Tachycardia—Doxorubicin—breast cancer	2.79e-05	0.000167	CcSEcCtD
Eprosartan—Headache—Capecitabine—breast cancer	2.78e-05	0.000166	CcSEcCtD
Eprosartan—Paraesthesia—Epirubicin—breast cancer	2.77e-05	0.000166	CcSEcCtD
Eprosartan—ABCC2—lymph node—breast cancer	2.77e-05	0.0314	CbGeAlD
Eprosartan—Hyperhidrosis—Doxorubicin—breast cancer	2.76e-05	0.000166	CcSEcCtD
Eprosartan—Dyspnoea—Epirubicin—breast cancer	2.75e-05	0.000165	CcSEcCtD
Eprosartan—Somnolence—Epirubicin—breast cancer	2.74e-05	0.000165	CcSEcCtD
Eprosartan—Anorexia—Doxorubicin—breast cancer	2.72e-05	0.000163	CcSEcCtD
Eprosartan—Nausea—Docetaxel—breast cancer	2.72e-05	0.000163	CcSEcCtD
Eprosartan—Feeling abnormal—Methotrexate—breast cancer	2.72e-05	0.000163	CcSEcCtD
Eprosartan—Dyspepsia—Epirubicin—breast cancer	2.72e-05	0.000163	CcSEcCtD
Eprosartan—Gastrointestinal pain—Methotrexate—breast cancer	2.7e-05	0.000162	CcSEcCtD
Eprosartan—Decreased appetite—Epirubicin—breast cancer	2.68e-05	0.000161	CcSEcCtD
Eprosartan—Hypotension—Doxorubicin—breast cancer	2.67e-05	0.00016	CcSEcCtD
Eprosartan—CYP2C9—endocrine gland—breast cancer	2.67e-05	0.0303	CbGeAlD
Eprosartan—Fatigue—Epirubicin—breast cancer	2.66e-05	0.00016	CcSEcCtD
Eprosartan—Pain—Epirubicin—breast cancer	2.64e-05	0.000158	CcSEcCtD
Eprosartan—Constipation—Epirubicin—breast cancer	2.64e-05	0.000158	CcSEcCtD
Eprosartan—Nausea—Capecitabine—breast cancer	2.63e-05	0.000158	CcSEcCtD
Eprosartan—Urticaria—Methotrexate—breast cancer	2.62e-05	0.000157	CcSEcCtD
Eprosartan—Body temperature increased—Methotrexate—breast cancer	2.61e-05	0.000156	CcSEcCtD
Eprosartan—Abdominal pain—Methotrexate—breast cancer	2.61e-05	0.000156	CcSEcCtD
Eprosartan—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.6e-05	0.000156	CcSEcCtD
Eprosartan—Insomnia—Doxorubicin—breast cancer	2.58e-05	0.000155	CcSEcCtD
Eprosartan—Paraesthesia—Doxorubicin—breast cancer	2.56e-05	0.000154	CcSEcCtD
Eprosartan—Dyspnoea—Doxorubicin—breast cancer	2.55e-05	0.000153	CcSEcCtD
Eprosartan—Feeling abnormal—Epirubicin—breast cancer	2.54e-05	0.000152	CcSEcCtD
Eprosartan—Somnolence—Doxorubicin—breast cancer	2.54e-05	0.000152	CcSEcCtD
Eprosartan—Gastrointestinal pain—Epirubicin—breast cancer	2.52e-05	0.000151	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—MMP3—breast cancer	2.52e-05	0.00043	CbGpPWpGaD
Eprosartan—Dyspepsia—Doxorubicin—breast cancer	2.51e-05	0.000151	CcSEcCtD
Eprosartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	2.51e-05	0.000429	CbGpPWpGaD
Eprosartan—CYP2C9—Metapathway biotransformation—CYP1A1—breast cancer	2.51e-05	0.000428	CbGpPWpGaD
Eprosartan—Decreased appetite—Doxorubicin—breast cancer	2.48e-05	0.000149	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—DKK1—breast cancer	2.46e-05	0.000421	CbGpPWpGaD
Eprosartan—Fatigue—Doxorubicin—breast cancer	2.46e-05	0.000148	CcSEcCtD
Eprosartan—Urticaria—Epirubicin—breast cancer	2.45e-05	0.000147	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCC1—breast cancer	2.45e-05	0.000419	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFC—breast cancer	2.44e-05	0.000418	CbGpPWpGaD
Eprosartan—Pain—Doxorubicin—breast cancer	2.44e-05	0.000146	CcSEcCtD
Eprosartan—Constipation—Doxorubicin—breast cancer	2.44e-05	0.000146	CcSEcCtD
Eprosartan—Body temperature increased—Epirubicin—breast cancer	2.44e-05	0.000146	CcSEcCtD
Eprosartan—Abdominal pain—Epirubicin—breast cancer	2.44e-05	0.000146	CcSEcCtD
Eprosartan—Hypersensitivity—Methotrexate—breast cancer	2.43e-05	0.000146	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—JAG2—breast cancer	2.41e-05	0.000411	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—HMOX1—breast cancer	2.39e-05	0.000409	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARGC1B—breast cancer	2.37e-05	0.000406	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—WNT1—breast cancer	2.37e-05	0.000405	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PLA2G4A—breast cancer	2.37e-05	0.000404	CbGpPWpGaD
Eprosartan—Asthenia—Methotrexate—breast cancer	2.37e-05	0.000142	CcSEcCtD
Eprosartan—Feeling abnormal—Doxorubicin—breast cancer	2.35e-05	0.000141	CcSEcCtD
Eprosartan—AGTR1—Signaling by GPCR—CSF2—breast cancer	2.34e-05	0.0004	CbGpPWpGaD
Eprosartan—Gastrointestinal pain—Doxorubicin—breast cancer	2.33e-05	0.00014	CcSEcCtD
Eprosartan—Pruritus—Methotrexate—breast cancer	2.33e-05	0.00014	CcSEcCtD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ABCB1—breast cancer	2.3e-05	0.000392	CbGpPWpGaD
Eprosartan—Hypersensitivity—Epirubicin—breast cancer	2.27e-05	0.000136	CcSEcCtD
Eprosartan—Urticaria—Doxorubicin—breast cancer	2.27e-05	0.000136	CcSEcCtD
Eprosartan—Body temperature increased—Doxorubicin—breast cancer	2.26e-05	0.000135	CcSEcCtD
Eprosartan—Abdominal pain—Doxorubicin—breast cancer	2.26e-05	0.000135	CcSEcCtD
Eprosartan—Diarrhoea—Methotrexate—breast cancer	2.26e-05	0.000135	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—NOTCH4—breast cancer	2.25e-05	0.000384	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—GZMB—breast cancer	2.24e-05	0.000382	CbGpPWpGaD
Eprosartan—Asthenia—Epirubicin—breast cancer	2.21e-05	0.000133	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX2—breast cancer	2.19e-05	0.000373	CbGpPWpGaD
Eprosartan—Pruritus—Epirubicin—breast cancer	2.18e-05	0.000131	CcSEcCtD
Eprosartan—Dizziness—Methotrexate—breast cancer	2.18e-05	0.000131	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—AGTR2—breast cancer	2.17e-05	0.000371	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL2—breast cancer	2.17e-05	0.000371	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—breast cancer	2.16e-05	0.000369	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTHLH—breast cancer	2.15e-05	0.000367	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BMP2—breast cancer	2.15e-05	0.000367	CbGpPWpGaD
Eprosartan—Diarrhoea—Epirubicin—breast cancer	2.11e-05	0.000127	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—breast cancer	2.11e-05	0.00036	CbGpPWpGaD
Eprosartan—Hypersensitivity—Doxorubicin—breast cancer	2.1e-05	0.000126	CcSEcCtD
Eprosartan—Vomiting—Methotrexate—breast cancer	2.1e-05	0.000126	CcSEcCtD
Eprosartan—Rash—Methotrexate—breast cancer	2.08e-05	0.000125	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—EDNRB—breast cancer	2.08e-05	0.000355	CbGpPWpGaD
Eprosartan—Dermatitis—Methotrexate—breast cancer	2.08e-05	0.000125	CcSEcCtD
Eprosartan—Headache—Methotrexate—breast cancer	2.07e-05	0.000124	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PGR—breast cancer	2.06e-05	0.000351	CbGpPWpGaD
Eprosartan—Asthenia—Doxorubicin—breast cancer	2.05e-05	0.000123	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—THBS1—breast cancer	2.05e-05	0.00035	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SYNJ2—breast cancer	2.04e-05	0.000349	CbGpPWpGaD
Eprosartan—Dizziness—Epirubicin—breast cancer	2.04e-05	0.000122	CcSEcCtD
Eprosartan—Pruritus—Doxorubicin—breast cancer	2.02e-05	0.000121	CcSEcCtD
Eprosartan—Vomiting—Epirubicin—breast cancer	1.96e-05	0.000118	CcSEcCtD
Eprosartan—Nausea—Methotrexate—breast cancer	1.96e-05	0.000117	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FLT1—breast cancer	1.95e-05	0.000334	CbGpPWpGaD
Eprosartan—Diarrhoea—Doxorubicin—breast cancer	1.95e-05	0.000117	CcSEcCtD
Eprosartan—Rash—Epirubicin—breast cancer	1.95e-05	0.000117	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—FGF3—breast cancer	1.95e-05	0.000332	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SQSTM1—breast cancer	1.95e-05	0.000332	CbGpPWpGaD
Eprosartan—Dermatitis—Epirubicin—breast cancer	1.94e-05	0.000117	CcSEcCtD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CG—breast cancer	1.94e-05	0.000331	CbGpPWpGaD
Eprosartan—Headache—Epirubicin—breast cancer	1.93e-05	0.000116	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—JAG1—breast cancer	1.92e-05	0.000328	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH3—breast cancer	1.91e-05	0.000327	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PARP1—breast cancer	1.91e-05	0.000327	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NDUFS3—breast cancer	1.9e-05	0.000325	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CALCA—breast cancer	1.89e-05	0.000323	CbGpPWpGaD
Eprosartan—Dizziness—Doxorubicin—breast cancer	1.89e-05	0.000113	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—RPS6—breast cancer	1.87e-05	0.000319	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF4—breast cancer	1.85e-05	0.000316	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL12—breast cancer	1.85e-05	0.000315	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCR4—breast cancer	1.85e-05	0.000315	CbGpPWpGaD
Eprosartan—Nausea—Epirubicin—breast cancer	1.83e-05	0.00011	CcSEcCtD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—MED12—breast cancer	1.83e-05	0.000312	CbGpPWpGaD
Eprosartan—Vomiting—Doxorubicin—breast cancer	1.82e-05	0.000109	CcSEcCtD
Eprosartan—AGTR1—Signaling Pathways—PAK1—breast cancer	1.81e-05	0.000309	CbGpPWpGaD
Eprosartan—Rash—Doxorubicin—breast cancer	1.8e-05	0.000108	CcSEcCtD
Eprosartan—Dermatitis—Doxorubicin—breast cancer	1.8e-05	0.000108	CcSEcCtD
Eprosartan—Headache—Doxorubicin—breast cancer	1.79e-05	0.000107	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—CHST9—breast cancer	1.79e-05	0.000305	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TCF7L2—breast cancer	1.78e-05	0.000304	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT2—breast cancer	1.77e-05	0.000303	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CG—breast cancer	1.76e-05	0.0003	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA3—breast cancer	1.75e-05	0.000298	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HSP90AA1—breast cancer	1.72e-05	0.000293	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH2—breast cancer	1.72e-05	0.000293	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CD—breast cancer	1.7e-05	0.000291	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CPT1A—breast cancer	1.7e-05	0.00029	CbGpPWpGaD
Eprosartan—Nausea—Doxorubicin—breast cancer	1.7e-05	0.000102	CcSEcCtD
Eprosartan—CYP2C9—Metabolism—COX11—breast cancer	1.69e-05	0.000289	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PRL—breast cancer	1.67e-05	0.000285	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—breast cancer	1.67e-05	0.000285	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ADAM10—breast cancer	1.64e-05	0.000281	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STK11—breast cancer	1.64e-05	0.000281	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PLG—breast cancer	1.63e-05	0.000278	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—breast cancer	1.62e-05	0.000276	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT2—breast cancer	1.61e-05	0.000275	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF10—breast cancer	1.6e-05	0.000273	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SHMT1—breast cancer	1.55e-05	0.000265	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CDA—breast cancer	1.55e-05	0.000265	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CD—breast cancer	1.55e-05	0.000264	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PDGFA—breast cancer	1.54e-05	0.000264	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—breast cancer	1.53e-05	0.000261	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFBR2—breast cancer	1.52e-05	0.00026	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—breast cancer	1.51e-05	0.000259	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ITPR1—breast cancer	1.5e-05	0.000256	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A5—breast cancer	1.49e-05	0.000255	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLCO1B1—breast cancer	1.49e-05	0.000255	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB4—breast cancer	1.49e-05	0.000254	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT5A—breast cancer	1.49e-05	0.000254	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP3—breast cancer	1.49e-05	0.000254	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CB—breast cancer	1.48e-05	0.000253	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—breast cancer	1.46e-05	0.000249	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—APRT—breast cancer	1.44e-05	0.000246	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SMAD4—breast cancer	1.44e-05	0.000246	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—ALB—breast cancer	1.44e-05	0.000245	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1R—breast cancer	1.43e-05	0.000245	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—CXCL8—breast cancer	1.43e-05	0.000244	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—FASN—breast cancer	1.41e-05	0.000242	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—breast cancer	1.41e-05	0.000241	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HES1—breast cancer	1.41e-05	0.00024	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NCOR1—breast cancer	1.4e-05	0.000239	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PLA2G4A—breast cancer	1.4e-05	0.000239	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CSF2—breast cancer	1.38e-05	0.000236	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGF1—breast cancer	1.38e-05	0.000236	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—RAF1—breast cancer	1.38e-05	0.000236	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NRG1—breast cancer	1.37e-05	0.000235	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—H2AFX—breast cancer	1.36e-05	0.000233	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—IL2—breast cancer	1.36e-05	0.000233	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ANGPTL4—breast cancer	1.35e-05	0.000231	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ESRRA—breast cancer	1.35e-05	0.000231	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—E2F1—breast cancer	1.35e-05	0.000231	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CB—breast cancer	1.35e-05	0.00023	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SPP1—breast cancer	1.3e-05	0.000222	CbGpPWpGaD
Eprosartan—ABCC2—Transmembrane transport of small molecules—RAF1—breast cancer	1.3e-05	0.000222	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—CXCL8—breast cancer	1.29e-05	0.000221	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	1.29e-05	0.00022	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB3—breast cancer	1.29e-05	0.00022	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HADHB—breast cancer	1.28e-05	0.000219	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPI—breast cancer	1.28e-05	0.000219	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR2—breast cancer	1.28e-05	0.000219	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL2—breast cancer	1.24e-05	0.000211	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TERT—breast cancer	1.23e-05	0.000211	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	1.23e-05	0.00021	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDH7A1—breast cancer	1.22e-05	0.000209	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDH1A1—breast cancer	1.22e-05	0.000209	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	1.21e-05	0.000207	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FGFR1—breast cancer	1.2e-05	0.000204	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HIF1A—breast cancer	1.18e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FHL2—breast cancer	1.17e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NME1—breast cancer	1.17e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PHGDH—breast cancer	1.17e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ADSL—breast cancer	1.17e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—UMPS—breast cancer	1.17e-05	0.000201	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—LDHB—breast cancer	1.15e-05	0.000197	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPSE—breast cancer	1.15e-05	0.000197	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BRIP1—breast cancer	1.15e-05	0.000197	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—LEP—breast cancer	1.15e-05	0.000197	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CAV1—breast cancer	1.14e-05	0.000195	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KDR—breast cancer	1.13e-05	0.000193	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ESR1—breast cancer	1.1e-05	0.000188	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMMR—breast cancer	1.09e-05	0.000187	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA3—breast cancer	1.09e-05	0.000187	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCC1—breast cancer	1.09e-05	0.000187	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—FN1—breast cancer	1.08e-05	0.000185	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NFKBIA—breast cancer	1.07e-05	0.000183	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOTCH1—breast cancer	1.06e-05	0.000181	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PPARGC1B—breast cancer	1.06e-05	0.000181	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—APC—breast cancer	1.04e-05	0.000177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KIT—breast cancer	1.04e-05	0.000177	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CG—breast cancer	1.04e-05	0.000177	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	1.03e-05	0.000176	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	1.03e-05	0.000176	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGF—breast cancer	1.03e-05	0.000175	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA4—breast cancer	9.99e-06	0.000171	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CA9—breast cancer	9.99e-06	0.000171	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—MAPK3—breast cancer	9.94e-06	0.00017	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	9.86e-06	0.000168	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	9.76e-06	0.000167	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—BRAF—breast cancer	9.76e-06	0.000167	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX2—breast cancer	9.73e-06	0.000166	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA2—breast cancer	9.73e-06	0.000166	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX4—breast cancer	9.61e-06	0.000164	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SULT1A1—breast cancer	9.61e-06	0.000164	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IGF1—breast cancer	9.51e-06	0.000162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT2—breast cancer	9.5e-06	0.000162	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—EGFR—breast cancer	9.46e-06	0.000162	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTA1—breast cancer	9.39e-06	0.00016	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—IDH1—breast cancer	9.39e-06	0.00016	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NAT2—breast cancer	9.28e-06	0.000159	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CD—breast cancer	9.13e-06	0.000156	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—PIK3CA—breast cancer	9.04e-06	0.000154	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SERPINE1—breast cancer	9.03e-06	0.000154	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—KRAS—breast cancer	8.94e-06	0.000153	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—NOS3—breast cancer	8.62e-06	0.000147	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	8.39e-06	0.000143	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—PIK3CA—breast cancer	8.21e-06	0.00014	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MDM2—breast cancer	8.18e-06	0.00014	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RAF1—breast cancer	8.15e-06	0.000139	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MED12—breast cancer	8.14e-06	0.000139	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—DPYD—breast cancer	8.14e-06	0.000139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—RELA—breast cancer	8.11e-06	0.000139	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—ERBB2—breast cancer	8.06e-06	0.000138	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALDOA—breast cancer	8.01e-06	0.000137	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MTOR—breast cancer	7.96e-06	0.000136	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CB—breast cancer	7.96e-06	0.000136	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA3—breast cancer	7.78e-06	0.000133	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A2—breast cancer	7.72e-06	0.000132	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CXCL8—breast cancer	7.65e-06	0.000131	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	7.64e-06	0.000131	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—HRAS—breast cancer	7.6e-06	0.00013	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CPT1A—breast cancer	7.57e-06	0.000129	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCG2—breast cancer	7.57e-06	0.000129	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTR—breast cancer	7.57e-06	0.000129	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1B—breast cancer	7.47e-06	0.000128	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HPGDS—breast cancer	7.42e-06	0.000127	CbGpPWpGaD
Eprosartan—AGTR1—GPCR downstream signaling—AKT1—breast cancer	7.39e-06	0.000126	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HBA1—breast cancer	7.37e-06	0.000126	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CASP3—breast cancer	7.32e-06	0.000125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL2—breast cancer	7.31e-06	0.000125	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—IL6—breast cancer	7.27e-06	0.000124	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTT1—breast cancer	7.2e-06	0.000123	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ACHE—breast cancer	7.2e-06	0.000123	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CCND1—breast cancer	7.12e-06	0.000122	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—JUN—breast cancer	7.11e-06	0.000121	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CTNNB1—breast cancer	7.05e-06	0.000121	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MMP9—breast cancer	6.92e-06	0.000118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—CDKN1A—breast cancer	6.89e-06	0.000118	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PTEN—breast cancer	6.87e-06	0.000117	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP17A1—breast cancer	6.81e-06	0.000116	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS1—breast cancer	6.74e-06	0.000115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ENO1—breast cancer	6.74e-06	0.000115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK8—breast cancer	6.73e-06	0.000115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	6.72e-06	0.000115	CbGpPWpGaD
Eprosartan—AGTR1—Signaling by GPCR—AKT1—breast cancer	6.71e-06	0.000115	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	6.63e-06	0.000113	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP2D6—breast cancer	6.61e-06	0.000113	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA2—breast cancer	6.49e-06	0.000111	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—SRC—breast cancer	6.38e-06	0.000109	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—FASN—breast cancer	6.3e-06	0.000108	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—BCHE—breast cancer	6.27e-06	0.000107	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—VEGFA—breast cancer	6.21e-06	0.000106	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC5A5—breast cancer	6.19e-06	0.000106	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—STAT3—breast cancer	6.15e-06	0.000105	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—SLC2A1—breast cancer	5.98e-06	0.000102	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NQO1—breast cancer	5.98e-06	0.000102	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MAPK3—breast cancer	5.87e-06	0.0001	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	5.86e-06	0.0001	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP3A4—breast cancer	5.83e-06	9.97e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	5.8e-06	9.92e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1B1—breast cancer	5.74e-06	9.8e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—MYC—breast cancer	5.71e-06	9.76e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TGFB1—breast cancer	5.7e-06	9.74e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HSP90AA1—breast cancer	5.62e-06	9.61e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—EGFR—breast cancer	5.59e-06	9.55e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOA1—breast cancer	5.47e-06	9.35e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—STK11—breast cancer	5.39e-06	9.21e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP19A1—breast cancer	5.39e-06	9.21e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—KRAS—breast cancer	5.28e-06	9.02e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.06e-06	8.65e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—COMT—breast cancer	5.01e-06	8.57e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTP1—breast cancer	4.99e-06	8.52e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—HMOX1—breast cancer	4.92e-06	8.41e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ITPR1—breast cancer	4.91e-06	8.39e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—PIK3CA—breast cancer	4.85e-06	8.29e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ABCB1—breast cancer	4.72e-06	8.07e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—TP53—breast cancer	4.69e-06	8.02e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—TYMS—breast cancer	4.64e-06	7.93e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NCOR1—breast cancer	4.58e-06	7.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GSTM1—breast cancer	4.58e-06	7.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PLA2G4A—breast cancer	4.58e-06	7.83e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—HRAS—breast cancer	4.49e-06	7.67e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—GPX1—breast cancer	4.39e-06	7.5e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CYP1A1—breast cancer	4.35e-06	7.43e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ERCC2—breast cancer	4.31e-06	7.37e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—IL6—breast cancer	4.29e-06	7.34e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—MTHFR—breast cancer	4.05e-06	6.92e-05	CbGpPWpGaD
Eprosartan—AGTR1—Signaling Pathways—AKT1—breast cancer	3.96e-06	6.77e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—CAV1—breast cancer	3.74e-06	6.39e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.57e-06	6.1e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CG—breast cancer	3.4e-06	5.82e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CD—breast cancer	2.99e-06	5.11e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—ALB—breast cancer	2.95e-06	5.05e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—NOS3—breast cancer	2.83e-06	4.83e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CB—breast cancer	2.61e-06	4.46e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTGS2—breast cancer	2.58e-06	4.42e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PTEN—breast cancer	2.25e-06	3.85e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—PIK3CA—breast cancer	1.59e-06	2.72e-05	CbGpPWpGaD
Eprosartan—CYP2C9—Metabolism—AKT1—breast cancer	1.3e-06	2.22e-05	CbGpPWpGaD
